Baxter to sell BPS business to Advent and Warburg Pincus for $4.25bn
Pharmaceutical Technology
MAY 9, 2023
Baxter International has signed a definitive agreement to sell its BioPharma Solutions (BPS) business to private equity investor Advent International and growth investor Warburg Pincus, in a deal valued at $4.25bn in cash. The business will offer services from clinical research to commercial deployment for clients.
Let's personalize your content